환자 유래 이종이식 모델 시장 보고서 : 동향, 예측 및 경쟁 분석(-2031년)

The future of the global patient-derived xenograft model market looks promising with opportunities in the pharmaceutical & biopharmaceutical company, academic & research institute, and CRO & CDMO markets. The global patient-derived xenograft model market is expected to grow with a CAGR of 9.6% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized cancer research, the rising adoption of preclinical oncology models, and the growing focus on targeted drug development.

• Lucintel forecasts that, within the tumor type category, breast cancer is expected to witness the highest growth over the forecast period.
• Within the end use category, CRO & CDMO is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market is experiencing rapid growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, the market is evolving with innovative technologies and increasing adoption across pharmaceutical and academic institutions. These developments are transforming how cancer therapies are tested and tailored to individual patients, ultimately improving treatment efficacy and reducing costs. The following key trends highlight the dynamic changes shaping this market, reflecting a shift towards more precise, efficient, and collaborative approaches in biomedical research and drug discovery.

• Increasing Adoption of PDX Models in Oncology Research: The demand for PDX models is rising as they provide a more accurate representation of human tumors compared to traditional cell lines. This trend is driven by the need for better preclinical testing of anticancer drugs, leading to higher success rates in clinical trials. Pharmaceutical companies and research institutions are investing heavily in PDX models to identify effective therapies, personalize treatment plans, and understand tumor heterogeneity. The growing adoption is also supported by technological improvements that make PDX models more accessible and reliable, thereby accelerating cancer research and drug development processes.
• Integration of Genomic and Molecular Profiling: The integration of genomic and molecular data with PDX models is transforming personalized medicine. By analyzing tumor genetics, researchers can select the most appropriate PDX models that mirror specific patient profiles. This approach enhances the predictive power of preclinical studies, enabling the development of targeted therapies. Advances in sequencing technologies and bioinformatics are facilitating this integration, leading to more precise treatment strategies. Consequently, this trend is improving the success rate of translating preclinical findings into effective clinical interventions, ultimately benefiting patient outcomes.
• Technological Innovations in PDX Model Development: Innovations such as humanized PDX models, 3D bioprinting, and microfluidic systems are enhancing the fidelity and functionality of PDX models. Humanized models, which incorporate human immune systems, allow for better evaluation of immunotherapies. 3D bioprinting enables the creation of complex tumor microenvironments, while microfluidic platforms facilitate high-throughput testing. These technological advancements are making PDX models more representative of actual human tumors, reducing the gap between preclinical and clinical results. As a result, the market is witnessing increased investment in cutting-edge technologies to improve model accuracy and predictive capabilities.
• Growing Focus on Ethical and Regulatory Aspects: As the use of PDX models expands, ethical considerations regarding animal welfare and regulatory compliance are gaining prominence. Efforts are underway to develop standardized protocols and guidelines to ensure humane treatment of animals and reproducibility of results. Regulatory agencies are also working to streamline approval processes for PDX-based research and therapies. This focus on ethics and regulation is fostering greater trust and acceptance among stakeholders, encouraging wider adoption of PDX models in clinical research. It also promotes responsible innovation, ensuring that advancements align with societal and ethical standards.
• Expansion of Collaborative Research and Data Sharing: The trend towards collaborative research and open data sharing is accelerating in the PDX market. Partnerships between academia, biotech firms, and pharmaceutical companies facilitate access to diverse tumor models and large datasets. Shared repositories and platforms enable researchers to validate findings, reduce duplication, and accelerate discovery. This collaborative approach enhances the robustness of preclinical studies and fosters innovation. As data sharing becomes more prevalent, it is expected to lead to more rapid development of effective therapies, reduce costs, and improve overall research efficiency in the PDX market.

In summary, these emerging trends are collectively reshaping the Patient-derived Xenograft Model Market by making research more precise, ethical, innovative, and collaborative. They are driving the development of more effective personalized therapies, reducing drug development timelines, and improving patient outcomes, ultimately transforming the landscape of cancer research and treatment.

Recent Developments in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market has experienced significant growth driven by advancements in cancer research, personalized medicine, and drug development. As researchers seek more accurate models to predict clinical outcomes, the market is evolving rapidly with technological innovations and increased adoption across research institutions and pharmaceutical companies. These developments are shaping the future landscape of oncology research, enabling more targeted therapies and improving patient outcomes. The following key developments highlight the recent trends and shifts within this dynamic market.

• Expansion of PDX Model Libraries: : The creation of extensive, diverse PDX repositories has enhanced research capabilities by providing a broader spectrum of tumor types and genetic profiles. This expansion allows for more precise drug testing and personalized treatment strategies, accelerating the development of targeted therapies and reducing time-to-market for new drugs.
• Integration of Genomic Technologies: : Incorporating advanced genomic and molecular profiling tools into PDX models has improved understanding of tumor heterogeneity and resistance mechanisms. This integration enables researchers to identify biomarkers and tailor treatments more effectively, leading to more successful clinical translations and improved patient outcomes.
• Adoption of Humanized PDX Models: : The development of humanized PDX models, which incorporate human immune system components, has revolutionized immunotherapy research. These models provide a more accurate representation of human immune responses, facilitating the testing of immuno-oncology drugs and accelerating their clinical development.
• Increased Use of Automation and AI: : Automation and artificial intelligence are being employed to streamline PDX model development, data analysis, and drug screening processes. This technological integration reduces costs, enhances reproducibility, and speeds up research workflows, thereby increasing the efficiency of drug discovery and development.
• Regulatory and Ethical Advancements: : Evolving regulatory frameworks and ethical standards are supporting the broader adoption of PDX models. Clear guidelines and increased acceptance by regulatory agencies are facilitating faster approval processes for drugs tested using PDX models, ultimately benefiting patients through quicker access to innovative therapies.

In summary, these recent developments are significantly impacting the Patient-derived Xenograft Model Market by improving model accuracy, expanding research capabilities, and accelerating drug development. The integration of genomic technologies, humanized models, automation, and regulatory support are collectively driving innovation, making PDX models more effective and accessible. Consequently, these advancements are poised to enhance personalized medicine approaches and improve clinical outcomes in oncology and beyond.

Strategic Growth Opportunities in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market is experiencing rapid growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, the demand for PDX models is increasing across various applications. This expansion is fueled by technological innovations, increasing investment in oncology research, and the need for targeted therapies. The market's evolution presents significant opportunities for pharmaceutical companies, research institutions, and biotech firms to develop more effective treatments. Understanding key growth areas across different applications can help stakeholders capitalize on emerging trends and accelerate the development of innovative solutions.

• Oncology Drug Development: The increasing need for predictive preclinical models is driving the adoption of PDX models in oncology drug testing. These models closely mimic human tumor biology, enabling more accurate assessment of drug efficacy and safety. This leads to faster, more reliable clinical translation, reducing drug development costs and timeframes. The impact is a more efficient pipeline for new cancer therapies, ultimately benefiting patients through quicker access to innovative treatments.
• Personalized Medicine: PDX models are crucial for developing personalized treatment plans by testing individual patient tumor responses to various therapies. This application enhances precision medicine, allowing clinicians to tailor treatments based on specific tumor characteristics. The impact is improved treatment outcomes, reduced adverse effects, and increased confidence in therapy selection, fostering a shift toward more individualized cancer care.
• Biomarker Discovery: The use of PDX models in identifying novel biomarkers is expanding, aiding in early diagnosis and prognosis of cancers. These models help validate potential biomarkers in a biologically relevant environment, accelerating their clinical application. The impact includes improved diagnostic accuracy, better patient stratification, and the development of targeted therapies, ultimately advancing personalized treatment strategies.
• Immuno-oncology Research: PDX models are increasingly integrated with humanized immune systems to study immune responses and evaluate immunotherapies. This application provides insights into tumor-immune interactions and helps optimize immunotherapeutic agents. The impact is the development of more effective immunotherapies, leading to improved patient response rates and expanding treatment options in oncology.
• Metastasis and Tumor Microenvironment Studies: PDX models are instrumental in understanding tumor metastasis and the tumor microenvironment. They enable researchers to investigate mechanisms of cancer spread and resistance, facilitating the development of anti-metastatic therapies. The impact is the potential to prevent or limit metastasis, improving survival rates and quality of life for cancer patients.

In summary, these growth opportunities are significantly shaping the Patient-derived Xenograft Model Market by enhancing drug development, personalized treatment, and understanding of cancer biology. The expansion across key applications is driving innovation, reducing development costs, and improving patient outcomes, positioning the market for sustained growth and impact in oncology research and therapy development.

Patient-derived Xenograft Model Market Driver and Challenges

The patient-derived xenograft model market is influenced by a variety of technological, economic, and regulatory factors. Advances in personalized medicine and cancer research have heightened demand for more accurate preclinical models, driving innovation and growth. Economic factors such as increased healthcare spending and funding for biomedical research further propel market expansion. Regulatory frameworks aimed at improving research standards and ethical considerations also shape market dynamics. However, challenges such as high development costs, complex regulatory approval processes, and ethical concerns surrounding animal models pose significant hurdles. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape effectively.

The factors responsible for driving the patient-derived xenograft model market include:

• Technological Advancements: The integration of genomic sequencing and biotechnological innovations has significantly improved the development of PDX models. These advancements enable more precise tumor engraftment and characterization, leading to better predictive accuracy for drug responses. As technology continues to evolve, the efficiency and reliability of PDX models increase, attracting pharmaceutical companies and research institutions. This progress accelerates drug discovery, personalized treatment strategies, and biomarker identification, thereby expanding the market. The ongoing innovation ensures that PDX models remain at the forefront of translational cancer research, fostering sustained growth.
• Rising Prevalence of Cancer: The increasing incidence of various cancers globally is a major driver for the PDX market. As cancer cases rise, there is a growing need for effective preclinical models to evaluate new therapies. PDX models, which closely mimic human tumor biology, are invaluable in understanding disease progression and testing targeted treatments. This demand is further amplified by the shift towards personalized medicine, requiring models that reflect individual patient tumor characteristics. Consequently, the market experiences heightened adoption and investment, supporting the development of more sophisticated PDX platforms to meet clinical and research needs.
• Growing Investment in Oncology Research: Increased funding from government agencies, private investors, and pharmaceutical companies is fueling the PDX market. These investments aim to accelerate the development of novel cancer therapies and improve existing treatment options. The focus on translational research and precision medicine has led to substantial financial support for establishing and expanding PDX repositories. This influx of capital enables research institutions to develop more diverse and representative models, facilitating faster drug screening and validation. As a result, the market benefits from enhanced research capabilities and a broader pipeline of potential therapeutics.
• Regulatory Support and Standardization: Regulatory agencies are increasingly recognizing the importance of PDX models in drug development and approval processes. Initiatives to establish standardized protocols and validation procedures improve reproducibility and reliability of research outcomes. Regulatory support encourages pharmaceutical companies to incorporate PDX models into their preclinical testing, reducing the risk of late-stage failures. This environment fosters confidence among stakeholders and promotes broader adoption of PDX technologies. As regulations evolve to facilitate ethical and efficient research, the market experiences growth driven by increased compliance and trust.
• Expansion of Personalized Medicine: The shift towards personalized treatment approaches in oncology is a significant market driver. PDX models enable the testing of therapies tailored to individual patient tumors, improving treatment efficacy and reducing adverse effects. This personalized approach necessitates the development of diverse and patient-specific models, expanding the scope and application of PDX technology. The demand for such models encourages collaborations between research institutions and biotech firms, fostering innovation. As healthcare providers increasingly adopt personalized strategies, the market for PDX models is expected to grow substantially, supporting more targeted and effective cancer treatments.

The challenges facing the patient-derived xenograft model market include:

• High Development and Maintenance Costs: Developing and maintaining PDX models is resource-intensive, requiring significant financial investment. The costs associated with tumor sample collection, model establishment, and ongoing animal care are substantial. These expenses can limit accessibility for smaller research entities and slow down the pace of innovation. Additionally, the need for specialized facilities and skilled personnel further escalates costs. High expenses may also impact the affordability and scalability of PDX models, hindering widespread adoption and limiting their integration into routine drug development processes.
• Complex Regulatory and Ethical Issues: The use of animal models raises ethical concerns and faces stringent regulatory scrutiny. Ethical debates surrounding animal welfare and the necessity of animal testing pose challenges for researchers and companies. Regulatory approval processes for PDX-based studies can be lengthy and complex, delaying research timelines and increasing costs. Variability in regulations across regions adds further complexity, complicating international collaborations. These issues can impede the rapid development and deployment of PDX models, affecting market growth and innovation.
• Limited Predictive Power and Tumor Heterogeneity: Despite their advantages, PDX models have limitations in fully replicating human tumor heterogeneity and microenvironment. Variability in engraftment success and differences between patient tumors and models can affect predictive accuracy. This limitation may lead to discrepancies in drug response data, impacting clinical translation. Additionally, the time required to establish PDX models can delay research and decision-making. Overcoming these scientific challenges is crucial for enhancing the reliability and utility of PDX models, which directly influences market confidence and expansion.

In summary, the Patient-derived Xenograft Model Market is driven by technological innovations, rising cancer prevalence, increased research investments, regulatory support, and the shift towards personalized medicine. However, high costs, ethical and regulatory complexities, and scientific limitations pose significant challenges. These factors collectively shape the market landscape, requiring stakeholders to balance innovation with ethical and financial considerations. The overall impact is a dynamic environment with substantial growth potential, provided that scientific and regulatory hurdles are effectively addressed. Continued advancements and strategic collaborations will be essential for unlocking the full potential of PDX models in cancer research and therapy development.

List of Patient-derived Xenograft Model Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies patient-derived xenograft model companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the patient-derived xenograft model companies profiled in this report include-

• Charles River Laboratories
• The Jackson Laboratory
• Crown Bioscience
• Altogen Labs
• Envigo
• WuXi AppTec
• Oncodesign
• Hera Biolabs
• XenTech
• Abnova Corp.

Patient-derived Xenograft Model Market by Segment

The study includes a forecast for the global patient-derived xenograft model market by tumor type, model type, end use, and region.

Patient-derived Xenograft Model Market by Tumor Type [Value from 2019 to 2031]:

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Others

Patient-derived Xenograft Model Market by Model Type [Value from 2019 to 2031]:

• Mice Model
• Rat Model

Patient-derived Xenograft Model Market by End Use [Value from 2019 to 2031]:

• Pharmaceutical & Biopharmaceutical Companies
• Academic & Research Institutes
• CRO's & CDMO's

Patient-derived Xenograft Model Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Patient-derived Xenograft Model Market

The patient-derived xenograft model market has experienced significant growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, countries are investing in innovative technologies and expanding their research capabilities. The United States, China, Germany, India, and Japan are leading this evolution, each contributing unique developments to enhance the understanding and application of PDX models. These countries are focusing on technological integration, regulatory support, and expanding research infrastructure to accelerate market growth and improve patient outcomes worldwide.

• United States: The US remains at the forefront of PDX model development, with increased funding from government agencies like the NIH and private sector investments. Recent advancements include the integration of genomic profiling with PDX models to personalize cancer treatments. Several biotech firms are developing high-throughput PDX platforms, improving drug screening efficiency. Regulatory agencies are also working on guidelines to streamline PDX-based drug approval processes, fostering faster clinical translation. The US's robust research ecosystem continues to drive innovation and market expansion in this sector.
• China: China has rapidly expanded its PDX market, driven by government initiatives supporting biotech innovation and cancer research. Recent developments include the establishment of specialized PDX research centers and increased collaborations between academia and industry. Chinese companies are focusing on developing cost-effective, scalable PDX models tailored to prevalent cancers like lung and gastric cancers. The country is also investing in automation and AI-driven data analysis to enhance model accuracy and throughput. These efforts aim to position China as a major player in global PDX research and drug development.
• Germany: Germany emphasizes precision medicine and has made notable progress in integrating PDX models into clinical research. Recent advancements include the development of patient-specific PDX models for rare cancers, aiding personalized treatment strategies. German biotech firms are adopting advanced imaging and molecular techniques to improve model characterization. The country benefits from strong regulatory frameworks that facilitate clinical translation of PDX-based therapies. Additionally, collaborations between academic institutions and industry are fostering innovation, positioning Germany as a key contributor to the European PDX market.
• India: India is witnessing rapid growth in the PDX market, supported by increasing cancer prevalence and a focus on affordable research solutions. Recent developments include the establishment of research hubs dedicated to PDX model development and validation. Indian biotech companies are working on cost-effective, scalable PDX models to support local drug discovery efforts. The government's initiatives to promote biotech innovation and collaborations with international research organizations are accelerating progress. Efforts are also underway to adapt PDX models for a broader range of cancers prevalent in the Indian population, aiming to improve treatment outcomes.
• Japan: Japan has made significant strides in integrating PDX models into its cancer research landscape. Recent advancements include the development of genetically engineered PDX models that better mimic human tumor biology. Japanese research institutions are focusing on combining PDX models with cutting-edge technologies like single-cell sequencing and AI analytics. The country's strong regulatory environment supports clinical translation and commercialization of PDX-based therapies. Japan's emphasis on precision medicine and innovative research collaborations continues to propel the growth of the PDX market, positioning it as a leader in Asia.

Features of the Global Patient-derived Xenograft Model Market

• Market Size Estimates: Patient-derived xenograft model market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Patient-derived xenograft model market size by tumor type, model type, end use, and region in terms of value ($B).
• Regional Analysis: Patient-derived xenograft model market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different tumor types, model types, end uses, and regions for the patient-derived xenograft model market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the patient-derived xenograft model market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the patient-derived xenograft model market by tumor type (lung cancer, pancreatic cancer, prostate cancer, breast cancer, and others), model type (mice model and rat model), end use (pharmaceutical & biopharmaceutical companies, academic & research institutes, and CRO's & CDMO's), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Patient-derived Xenograft Model Market by Tumor Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Tumor Type
• 4.3 Lung Cancer : Trends and Forecast (2019-2031)
• 4.4 Pancreatic Cancer : Trends and Forecast (2019-2031)
• 4.5 Prostate Cancer : Trends and Forecast (2019-2031)
• 4.6 Breast Cancer : Trends and Forecast (2019-2031)
• 4.7 Others : Trends and Forecast (2019-2031)

5. Global Patient-derived Xenograft Model Market by Model Type

• 5.1 Overview
• 5.2 Attractiveness Analysis by Model Type
• 5.3 Mice Model : Trends and Forecast (2019-2031)
• 5.4 Rat Model : Trends and Forecast (2019-2031)

6. Global Patient-derived Xenograft Model Market by End Use

• 6.1 Overview
• 6.2 Attractiveness Analysis by End Use
• 6.3 Pharmaceutical & Biopharmaceutical Companies : Trends and Forecast (2019-2031)
• 6.4 Academic & Research Institutes : Trends and Forecast (2019-2031)
• 6.5 CRO's & CDMO's : Trends and Forecast (2019-2031)

7. Regional Analysis

• 7.1 Overview
• 7.2 Global Patient-derived Xenograft Model Market by Region

8. North American Patient-derived Xenograft Model Market

• 8.1 Overview
• 8.2 North American Patient-derived Xenograft Model Market by Tumor Type
• 8.3 North American Patient-derived Xenograft Model Market by End Use
• 8.4 The United States Patient-derived Xenograft Model Market
• 8.5 Canadian Patient-derived Xenograft Model Market
• 8.6 Mexican Patient-derived Xenograft Model Market

9. European Patient-derived Xenograft Model Market

• 9.1 Overview
• 9.2 European Patient-derived Xenograft Model Market by Tumor Type
• 9.3 European Patient-derived Xenograft Model Market by End Use
• 9.4 German Patient-derived Xenograft Model Market
• 9.5 French Patient-derived Xenograft Model Market
• 9.6 Italian Patient-derived Xenograft Model Market
• 9.7 Spanish Patient-derived Xenograft Model Market
• 9.8 The United Kingdom Patient-derived Xenograft Model Market

10. APAC Patient-derived Xenograft Model Market

• 10.1 Overview
• 10.2 APAC Patient-derived Xenograft Model Market by Tumor Type
• 10.3 APAC Patient-derived Xenograft Model Market by End Use
• 10.4 Chinese Patient-derived Xenograft Model Market
• 10.5 Indian Patient-derived Xenograft Model Market
• 10.6 Japanese Patient-derived Xenograft Model Market
• 10.7 South Korean Patient-derived Xenograft Model Market
• 10.8 Indonesian Patient-derived Xenograft Model Market

11. ROW Patient-derived Xenograft Model Market

• 11.1 Overview
• 11.2 ROW Patient-derived Xenograft Model Market by Tumor Type
• 11.3 ROW Patient-derived Xenograft Model Market by End Use
• 11.4 Middle Eastern Patient-derived Xenograft Model Market
• 11.5 South American Patient-derived Xenograft Model Market
• 11.6 African Patient-derived Xenograft Model Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Tumor Type
  • 13.2.2 Growth Opportunity by Model Type
  • 13.2.3 Growth Opportunity by End Use
• 13.3 Emerging Trends in the Global Patient-derived Xenograft Model Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Charles River Laboratories
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 The Jackson Laboratory
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Crown Bioscience
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Altogen Labs
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Envigo
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 WuXi AppTec
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Oncodesign
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 Hera Biolabs
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 XenTech
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 Abnova Corp.
  • Company Overview
  • Patient-derived Xenograft Model Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us